Antibiotics in Urology - New Essentials

Urologic Clinics of North America

Volumn 35, Issue 1, 2008, Pages 69-79

  Wagenlehner, F M E ^a   Weidner, W ^a   Naber, K G ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1BETA METHYLCARBAPENEM DERIVATIVE; 3 [(6,7 DIHYDRO 5H PYRROLO[1,2 A]IMIDAZOL 6 YL)THIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 [1 (2 THIAZOLIN 2 YL) 3 AZETIDINYL] 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; DOXYCYCLINE; ERTAPENEM; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; IMIPENEM; MEROPENEM; MEZLOCILLIN; NITROFURANTOIN; NORFLOXACIN; PIVMECILLINAM; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; SULFONAMIDE; SULTAMICILLIN; TEMOCILLIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL CELL; BACTERIAL STRAIN; CITROBACTER FREUNDII; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTITIS; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEUS; PSEUDOMONAS; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS SAPROPHYTICUS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 36448951951     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.09.002     Document Type: Review

References (67)

1. Bouza E., San Juan R., Munoz P., et al. A European perspective on nosocomial urinary tract infections. I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect 7 10 (2001) 523-531
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113 Suppl 1A (2002) 5S-13S
3. Maki D.G., and Tambyah P.A. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 7 2 (2001) 342-347
4. Ruden H., Gastmeier P., Daschner F.D., et al. Nosocomial and community-acquired infections in Germany: summary of the results of the First National Prevalence Study (NIDEP). Infection 25 4 (1997) 199-202
5. Wagenlehner F.M., Niemetz A., Dalhoff A., et al. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000. Int J Antimicrob Agents 19 6 (2002) 557-564
6. Elhanan G., Sarhat M., and Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 35 3 (1997) 283-288
7. Gupta K., Hooton T.M., and Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135 1 (2001) 41-50
8. Talan D.A., Stamm W.E., Hooton T.M., et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 283 12 (2000) 1583-1590
9. Zhanel G.G., Hisanaga T.L., Laing N.M., et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 26 5 (2005) 380-388
10. Naber KG, Schito GC, Gualco L (on behalf of the ARESC working group). An international survey on etiology and susceptibility of uropathogens isolated from women with uncomplicated UTI: the ARESC study. In: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, 2007.
11. Gordon K.A., and Jones R.N. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 45 4 (2003) 295-301
12. Drlica K., and Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61 3 (1997) 377-392
13. Lehn N. Mechanismen der resistenzentwicklung gegen antibiotika: epidemiologie. In: Adam D., Doerr H.W., Link H., et al. (Eds). Die infektiologie (2004), Springer-Verlag, Berlin 82-98
14. McLuskey K., Cameron S., Hammerschmidt F., et al. Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavin-dependent mechanism. Proc Natl Acad Sci U S A 102 40 (2005) 14221-14226
15. Pechere J.C., Michea-Hamzhepour M., and Kohler T. [Antibiotic efflux, a mechanism of multiple resistance in Pseudomonas aeruginosa]. Bull Acad Natl Med 182 3 (1998) 599-612 [discussion: 595-613] [in French]
16. Piddock L.J. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58 Suppl 2 (1999) 11-18
17. Tanaka M., Onodera Y., Uchida Y., et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 41 11 (1997) 2362-2366
18. Navia M.M., Ruiz J., Ribera A., et al. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii. J Antimicrob Chemother 44 6 (1999) 743-748
19. Linde H.J., Schmidt M., Fuchs E., et al. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother 45 5 (2001) 1553-1557
20. Fontana R., Ligozzi M., Pittaluga F., et al. Intrinsic penicillin resistance in enterococci. Microb Drug Resist 2 2 (1996) 209-213
21. Marshall C.G., and Wright G.D. The glycopeptide antibiotic producer Streptomyces toyocaensis NRRL 15009 has both D-alanyl-D-alanine and D-alanyl-D-lactate ligases. FEMS Microbiol Lett 157 2 (1997) 295-299
22. Burchall J.J., Elwell L.P., and Fling M.E. Molecular mechanisms of resistance to trimethoprim. Rev Infect Dis 4 2 (1982) 246-254
23. Park H., Bradrick T.D., and Howell E.E. A glutamine 67-histidine mutation in homotetrameric R67 dihydrofolate reductase results in four mutations per single active site pore and causes substantial substrate and cofactor inhibition. Protein Eng 10 12 (1997) 1415-1424
24. Then R.L. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. Rev Infect Dis 4 2 (1982) 261-269
25. Livermore D.M. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 16 Suppl 1 (2000) S3-S10
26. Stapleton P., Wu P.J., King A., et al. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39 11 (1995) 2478-2483
27. Chaves J., Ladona M.G., Segura C., et al. SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob Agents Chemother 45 10 (2001) 2856-2861
28. Yang Y.J., and Livermore D.M. Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii. Antimicrob Agents Chemother 32 9 (1988) 1385-1391
29. Bonnet R., De Champs C., Sirot D., et al. Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 43 11 (1999) 2671-2677
30. Patterson J.E. Extended-spectrum beta-lactamases. Semin Respir Infect 15 4 (2000) 299-307
31. Jones R.N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119 2 Suppl (2001) 397S-404S
32. Culebras E., and Martinez J.L. Aminoglycoside resistance mediated by the bifunctional enzyme 6′-N-aminoglycoside acetyltransferase-2″-O-aminoglycoside phosphotransferase. Front Biosci 4 (1999) D1-D8
33. The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms: combined results of surveys in eight regions of the world. J Chemother 7 Suppl 2 (1995) 17-30
34. Yan F., Munos J.W., Liu P., et al. Biosynthesis of fosfomycin, re-examination and re-confirmation of a unique Fe(II)- and NAD(P)H-dependent epoxidation reaction. Biochemistry 45 38 (2006) 11473-11481
35. Higgins L.J., Yan F., Liu P., et al. Structural insight into antibiotic fosfomycin biosynthesis by a mononuclear iron enzyme. Nature 437 7060 (2005) 838-844
36. Schito G.C. Why fosfomycin trometamol as first line therapy for uncomplicated UTI?. Int J Antimicrob Agents 22 Suppl 2 (2003) 79-83
37. Ungheri D., Albini E., and Belluco G. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 14 3 (2002) 237-240
38. Lecomte F., and Allaert F.A. Le traitement monodose de la cystite par fosfomycin trometamol: analyse de 15 essais comparatifs portant sur 2048 malades. Med Mal Infect 26 (1996) 338-343
39. Patel S.S., Balfour J.A., and Bryson H.M. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53 4 (1997) 637-656
40. Simon C., and Stille W. Antibiotika-therapie in klinik und praxis. 10th edition (2000), Schattauer, Stuttgart (Germany)
41. Hof H. [Antimicrobial therapy with nitroheterocyclic compounds, for example, metronidazole and nitrofurantoin]. Immun Infekt 16 6 (1988) 220-225 [in German]
42. Hooton T.M. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 17 2 (2003) 303-332
43. Warren J.W., Abrutyn E., Hebel J.R., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 29 4 (1999) 745-758
44. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 21 11 (1999) 1864-1872
45. Lancini G., and Parenti F. Antibiotics: an integrated view (1982), Springer-Verlag, New York
46. Graninger W. Pivmecillinam: therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 22 Suppl 2 (2003) 73-78
47. Nicolle L.E. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 46 Suppl 1 (2000) 35-39 [discussion: 63-35]
48. Nicolle L.E., Madsen K.S., Debeeck G.O., et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 34 7 (2002) 487-492
49. Livermore D.M., and Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 14 9 (2006) 413-420
50. Ena J., Arjona F., Martinez-Peinado C., et al. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68 6 (2006) 1169-1174
51. Shah P.M., and Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 52 4 (2003) 538-542
52. Hammond M.L. Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother 53 Suppl 2 (2004) II7-II9
53. Jones R.N., Sader H.S., and Fritsche T.R. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 52 1 (2005) 71-74
54. Naber K, Redman R, Kotey P, et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. Presented at the 25th ICC, 17th ECCMID. Munich, March 31-April 3, 2007.
55. Kumagai T., Tamai S., Abe T., et al. Current status of oral carbapenem development. Current Medicinal Chemistry - Anti-Infective Agents 1 (2002) 1-14
56. van Ogtrop M.L. CS-834 (Sankyo). IDrugs 2 3 (1999) 254-258
57. Li J., Nation R.L., Turnidge J.D., et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 6 9 (2006) 589-601
58. Hachem R.Y., Chemaly R.F., Ahmar C.A., et al. Colistin is effective in the treatment of multidrug-resistant Pseudomonas aeruginosa infections in cancer patients. Antimicrob Agents Chemother 51 6 (2007) 1905-1911
59. Hampel B., Feike M., Koeppe P., et al. Pharmacokinetics of temocillin in volunteers. Drugs 29 Suppl 5 (1985) 99-102
60. Wagenlehner F.M., Lehn N., Witte W., et al. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections. Chemotherapy 51 2-3 (2005) 64-69
61. Allen N.E., Hobbs J.N., and Alborn Jr. W.E. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother 31 7 (1987) 1093-1099
62. Snydman D.R., Jacobus N.V., McDermott L.A., et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 44 12 (2000) 3447-3450
63. De Bruin MF, Tally FP. Efficacy and safety of daptomycin for the treatment of bacteremia and serious infections due to gram-positive bacteria. Presented at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, GA, March 5-9, 2000.
64. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 8 8 (1999) 1195-1202
65. Conte Jr. J.E., Golden J.A., Kipps J., et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46 5 (2002) 1475-1480
66. MacGowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 51 Suppl 2 (2003) II17-II25
67. Wagenlehner F.M., Wydra S., Onda H., et al. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 47 12 (2003) 3789-3794